Bone Accounts Payable from 2010 to 2024
BBLGW Stock | USD 28.49 3.29 10.35% |
Accounts Payable | First Reported 2014-12-31 | Previous Quarter 146.2 K | Current Value 231.9 K | Quarterly Volatility 468 K |
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
Bone | Accounts Payable |
Latest Bone Biologics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Bone Biologics Corp over the last few years. An accounting item on the balance sheet that represents Bone Biologics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bone Biologics Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Bone Biologics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Bone Accounts Payable Regression Statistics
Arithmetic Mean | 168,466 | |
Geometric Mean | 109,061 | |
Coefficient Of Variation | 69.99 | |
Mean Deviation | 86,458 | |
Median | 119,776 | |
Standard Deviation | 117,907 | |
Sample Variance | 13.9B | |
Range | 464.5K | |
R-Value | 0.27 | |
Mean Square Error | 13.9B | |
R-Squared | 0.07 | |
Significance | 0.33 | |
Slope | 7,147 | |
Total Sum of Squares | 194.6B |
Bone Accounts Payable History
About Bone Biologics Financial Statements
Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Accounts Payable | 360.7 K | 202.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.